VacZine Analytics  
MarketVIEW: Chikungunya virus vaccines

Published: July 2018

Chikungunya virus (CHIK) is an arthropod-borne RNA virus (arbovirus) which causes an acute illness including fever, skin rash, and incapacitating arthralgia. In some cases, the virus can cause recurrent disease (post-CHIK rheumatic disorder), neurological complications and severe neonatal disease (encephalopathy). CHIK is not generally considered a life-threatening disease, with an estimated case-fatality rate of 0.1%. However, concerns are increasing. In 2016, the Brazilian Ministry of Health recognised more than 200 deaths related to CHIK infection.

A number of potential CHIK vaccine candidates (based on various approaches) are now in the clinical stages of development including those from PaxVax, Inc, Themis Bio GmbH, Valneva Austria GmbH. The PaxVax, Inc and Themis Bio vaccine candidates received fast-track designation by the FDA and EU in May/June 2018 respectively. A CHIK vaccine could be used in vulnerable populations in both endemic public/private markets and possibly in Western travelers (profile dependent).

This MarketVIEW product is a comprehensive commercial evaluation containing an Executive Presentation (~110 slides) and MS Excel Workbook (.xls) examining the potential (value/volume) of a prophylatic Chikungunya vaccine to 2035. The prospects of the vaccine in “First time” and “Repeat” Western travelers (Visiting Friends/Family and Business + Other) , endemic markets (public + private) and for military/domestic stockpile use are discussed with assumptions clearly outlined. A full review of disease background, latest epidemiology/outbreaks and competitor/R&D activity is also provided.

THIS PRODUCT IS A SUMMARY PRESENTATION (110 slides, .pdf form) + FORECAST MODEL (.xls)

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV005 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2018 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains